总金额6.7亿美元，和铂医药就一款自免双抗与大冢制药达成合作

Core Viewpoint - Heptagon Pharmaceuticals has entered into a significant global strategic collaboration with Otsuka Pharmaceutical, granting exclusive rights to develop, manufacture, and commercialize its proprietary BCMA×CD3 bispecific T cell engager HBM7020 outside of Greater China for a total transaction value of $670 million [1][2]. Group 1: Recent Transactions - The collaboration with Otsuka Pharmaceutical marks Heptagon's second cross-border business development (BD) transaction in 2023, following a major deal with AstraZeneca worth over 30 billion yuan [2][3]. - Under the agreement with Otsuka, Heptagon will receive an upfront payment of $47 million and potential milestone payments totaling up to $623 million, along with tiered royalties based on future net sales [2]. - In March 2023, Heptagon entered into a global strategic partnership with AstraZeneca, which included an upfront payment of $175 million and potential additional payments of up to $4.4 billion [3]. Group 2: Financial Performance - Heptagon Pharmaceuticals reported a revenue of $89.5 million in 2023, a year-on-year increase of 119.9%, achieving a net profit of $22.8 million, marking a turnaround from previous losses [5]. - However, in 2024, the company experienced a significant decline in revenue, recording $38.1 million, a decrease of 57.43%, and a net profit of $2.7 million, down 88% year-on-year [6]. Group 3: Product Development - Heptagon currently has 19 products in its pipeline, targeting various indications including tumors and immune diseases [6]. - The most advanced product is HBM9161, which is expected to complete approval in the second half of 2024 and potentially become the company's first commercialized product by 2026 [6].